Regeneron Tries To Put Focus On PD-1 Program, Not Sluggish Autoimmune Sales
Executive Summary
Regeneron promised big things for PD-1 inhibitor cemiplimab during its first quarter earnings call, including studies to test its potential in lung cancer compared to Merck's Keytruda. It hopes to launch the antibody in a smaller indication later this year.
You may also be interested in...
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
The latest drug development news and highlights from our FDA Performance Tracker.
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
The latest drug development news and highlights from our FDA Performance Tracker.
Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer
In addition to skin cancer, the PD-1 inhibitor cemiplimab is being positioned for a range of other tumor types with Phase III studies ongoing in lung and cervical cancers.